DOCSLIB.ORG

Merck & the Latest Mega- Merger in the Healthcare Sector

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Merck & the Latest Mega- Merger in the Healthcare Sector A spoonful of premium makes the medicine go down: Merck & the latest mega- merger in the healthcare sector Merck KGaA, Market Cap (as of 26/09/2014): €31.4bn Sigma-Aldrich Corp., Market Cap (as of 26/09/2014): $16.2bn On September 22, 2014, the German drug and chemicals company Merck KGaA announced a definitive agreement under which it will acquire the US-based leading life science consumables supplier Sigma-Aldrich for $17bn, creating one of the leading players in the $130bn global life science industry. Merck is a leading global pharmaceutical, chemical and life science company with approximately 38,000 employees across 66 countries and generating total revenue of €11.1bn in 2013. Merck's business divisions (Merck Serono, Consumer Health, Performance Materials and Merck Millipore) are controlled by Merck KGaA, in which Merck family holds about 70% interest while public shareholders own the remainder 30%. The announced deal is the biggest in the history of the company, surpassing the previous record set by the €10.3bn acquisition of the Swiss biotech company Serono. The leading life science and technology company Sigma-Aldrich manufactures and distributes more than 230,000 chemicals, biochemicals and other essential products to more than 1.4m customers globally, in research and applied labs as well as to industrial and commercial clients. The St. Louis-based company, of the largest makers of chemicals and biological materials used in scientific laboratories, operates in 37 countries with approximately 9,000 employees worldwide and generated total revenue of $2.7bn in 2013, half of which coming from academic labs, drug companies and industrial manufacturers. Thanks to this transaction, Merck has the chance to further diversify its business model by entering the life science sector, characterized by a stable growth pattern and high margins. In fact, the investments in pharmaceutical R&D have not yielded the hoped results: over the last 10 years the company has not been able to develop or discover any new drugs since its last major drug was approved in 2003. As a matter of fact, the pharmaceutical side of the business, which represents 55% company’s revenues (FY2013), is clearly turning out to be uncompetitive: the increased competition, the healthcare reforms and the government’s cost containment measures put further pressure on margins and on sustainable long-term growth perspectives, thus forcing companies in the pharmaceutical sector to move towards higher profit segments like rare disease treatments and high-tech products. According to Merck, the acquisition of Sigma-Aldrich is expected to significantly increase the scale of Merck’s operations and to generate substantial synergies mainly thanks to the optimization of R&D portfolio and to the consolidation of both the manufacturing footprint and the global distribution platform (in particular in US and in Asia). Indeed, €260m of synergies per annum are expected to be fully achieved in three years after the closing. The benefits will be partially offset by €400m of integration costs spread on the 2015-2018 period, thus leading to a 24% increase of the FY2013 pro-forma EBITDA (adjusted for one-off items) and a ca. 300 basis points increase of the EBITDA margin. Moreover, the credit profile of Merck is expected to improve thanks to the lower business risk arising from more stable cash flows and a higher degree of geographic diversification. Merck’s offer price stands at $140 per share, a 37% premium to the latest closing price of $102.37 on September 19, 2014. Accordingly, the total consideration is ca. $17bn, which implies an EV/EBITDA of 20.1x, fairly in line with the average of the US biotech sector. The transaction, expected to be immediately accretive in terms of EPS adjusted for one-off items, will be settled entirely in cash and debt. For this purpose, Merck has been granted bank loans and bridge financing as the take out financing structure will be formed by €4bn of bank loans, €7bn of bonds and €2bn of cash-in-hand (in total €13bn, ca. $17bn). Merck’s stock price reacted positively to the news, recording an increase by 4.14% upon announcement and reflecting a genuine support of investors. Similarly, Sigma-Aldrich share price rallied from $102.37 to $136.40 (+33.24%) upon announcement. The deal is expected to be closed in mid-2015, subject to regulatory approvals and other customary closing conditions as well as Sigma-Aldrich shareholders’ approval. Guggenheim Securities and J.P. Morgan are acting as financial advisers to Merck while Sigma- Aldrich is advised by Morgan Stanley. All the views expressed are opinions of Bocconi Students Investment Club members and can in no way be associated with Bocconi University. All the financial recommendations offered are for educational purposes only. Bocconi Students Investment Club declines any responsibility for eventual losses you may incur implementing all or part of the ideas contained in this website. The Bocconi Students Investment Club is not authorised to give investment advice. Information, opinions and estimates contained in this report reflect a judgment at its original date of publication by Bocconi Students Investment Club and are subject to change without notice. The price, value of and income from any of the securities or financial instruments mentioned in this report can fall as well as rise. Bocconi Students Investment Club does not receive compensation and has no business relationship with any mentioned company. Copyright © Sep-14 BSIC | Bocconi Students Investment Club Tags: accretive, healthcare, J.P. Morgan, JP Morgan, life science consumables supplier, M&A, Merck KGaA, Merck, merger, Morgan Stanley, Sigma-Aldrich, pharma, pharmaceutical .
Load more

Recommended publications
  • Certificate ISO 14001 From
    CERTIFICATE This is to certify that Merck KGaA Frankfurter Strasse 250 64293 Darmstadt Germany with the organizational units/sites as listed in the annex has implemented and maintains an Environmental Management System. Scope: Development, production and distribution of pharmaceuticals, chemical products and analytical systems. Through an audit, documented in a report, it was verified that the management system fulfills the requirements of the following standard: ISO 14001 : 2015 Certificate registration no. 005356 UM15 Valid from 2020-12-17 Valid until 2023-12-16 Date of certification 2020-11-18 DQS GmbH Markus Bleher Managing Director Accredited Body: DQS GmbH, August-Schanz-Straße 21, 60433 Frankfurt am Main, Germany 1 / 19 Annex to certificate Registration No. 005356 UM15 Merck KGaA Frankfurter Strasse 250 64293 Darmstadt Germany Location Scope 005356 Development, production and distribution of Merck KGaA pharmaceuticals, chemical products and Frankfurter Straße 250 analytical systems. 64293 Darmstadt Including: Real Estate GmbH Merck Performance Materials Germany GmbH Merck Healthcare KGaA With regional offices at: Roesslerstrasse 96 64293 Darmstadt Waldstrasse 3 64331 Weiterstadt 450237 Merck S.A. Production and distribution of pharmaceuticals Estrada dos Bandeirantes, 1099 and chemical products. Rio de Janeiro - RJ 22710-571 Brazil 450240 Merck Serono SA Production and distribution of Zone Industrielle de l´Ouriettaz pharmaceuticals. 1170 Aubonne Switzerland 450325 Merck Serono SA Development and production of Corsier-sur-Vevey pharmaceuticals. Rte de Fenil 25 1804 Fenil-sur-Vevey Switzerland This annex (edition: 2020-11-18) is only valid in connection with the above-mentioned certificate. 2 / 19 Annex to certificate Registration No. 005356 UM15 Merck KGaA Frankfurter Strasse 250 64293 Darmstadt Germany Location Scope 450241 Merck & Cie Production of chemical products.
    [Show full text]
  • Geschäftsbericht 2017
    350 Geschäftsbericht 2017 1668 Auszug aus dem „Apotheken-Privileg“ des Landesherren für den Unternehmensgründer FRIEDRICH JACOB MERCK: „ [Er soll die Apotheke] der ordnung gemeess mit guten frischen, zu ein= und anderen Curen dienlichen heil- samen Medicamentis und wahren also genugsamlich versehen, und damit fort und fort würklich continuiren, daß kein Mangel erscheine.“ 2018 STEFAN OSCHMANN Vorsitzender der Geschäftsleitung und CEO von Merck „ Wissenschaftliche Neu- gierde treibt uns seit 350 Jahren an. Durch sie wurden wir Techno logie- Pioniere. Und jetzt gestalten wir die digi tale Revolution mit.“ DIE ZUKUNFT SPRICHT SIMON CLARK sechs Jungforscherinnen und -forscher promoviert im Bereich Atmosphä- rische Physik an der University of Exeter. Auch in seinen YouTube- Videos geht es vor allem um physi- kalische Themen. „ Die Dinge verbessern sich nur, wenn es Leute gibt, die ver- rückte Ideen haben und etwas Neues ausprobieren.“ Treibt Merck frische Ideen voran? Die Antwort finden Sie auf Seite 10. SAMUEL CUNHA ist ein brasilianischer Parasitologe, der seine Leidenschaft für Biologie mit vielen Fans auf YouTube teilt. „ Um leidenschaftlich zu bleiben, muss man immer an die Zukunft denken, an das mögliche Ergebnis seiner Arbeit.“ Wie hält es Merck mit diesem Grundsatz? Die Antwort lesen Sie auf Seite 11. EVA AMSEN ist promovierte Biochemikerin, Autorin und Wissenschaftsvermittlerin in London. „ Für Wissen- schaftler ist es wichtig, dass sie sich nicht nur mit ihren Kollegen austauschen, sondern auch mit Menschen aus völlig anderen Bereichen – zum Bei- spiel mit Künstlern.“ Wird interdisziplinärer Austausch bei Merck gelebt? Die Antwort lesen Sie auf Seite 13. INÉS DAWSON ist promovierte Biologin in Oxford und beliebte YouTuberin. „ Forschung und Kreativität sollten Hand in Hand gehen, da nicht alle Probleme eine eindeutige Lösung haben.“ Fördert Merck Kreativität? Die Antwort finden Sie auf Seite 14.
    [Show full text]
  • MERCK Kgaa DARMSTADT, GERMANY
    MERCK KGaA DARMSTADT, GERMANY Annual Financial Statements 2016 DISCLAIMER Publication of Merck KGaA, Darmstadt, Germany. In the United States and Canada the subsidiaries of Merck KGaA, Darmstadt, Germany, operate as EMD Serono in Healthcare, MilliporeSig- ma in Life Science and EMD Performance Materials. To reflect such fact and to avoid any misconception of the reader of the publication certain logos, terms and names of businesses of the publication have been substituted or additional descriptions have been added. This version of the publication, therefore, slightly deviates from the otherwise identical version of the publication provided outside the United States and Canada. For nearly 350 years, curious people at our company have been bringing ideas to life. As a global science and technology company, a passion for research and discovery is our most valuable resource. With our three business sectors, namely Healthcare, Life Science and Performance Materials, we improve the quality of life of patients, in- crease the success of our customers, and offer solutions for diverse challenges. Curiosity is and remains our strongest driving force for future-oriented innovations. Annual Financial Statements 3 Combined Management Annual Financial Statements Report 112 – 158 03 – 110 112 Balance Sheet as of December 31, 2016 113 Income Statement from the period 003 Fundamental Information about the Group from January 1 to December 31, 2016 003 The Group 114 Notes to the Annual Financial Statements 010 Objectives and strategies 115 Notes to the Balance Sheet 016 Internal Management System 125 Notes to the Income Statement 020 Corporate Responsibility 129 Other Disclosures 028 Research and development 132 Members of the Executive Board of Merck KGaA, 040 People Darmstadt, Germany 133 Supervisory Board 046 Report on Economic Position 134 Disclosures in accordance with section 160 (1) no.
    [Show full text]
  • Annual Financial Statements TABLE of CONTENTS Annual Financial Statements
    Annual Financial Statements TABLE OF CONTENTS Annual Financial Statements Combined Annual Financial Management Report Statements 4 Fundamental Information 140 Balance Sheet as of December 31, 2020 about the Group 141 Income Statement for the period 4 The Group from January 1 to December 31, 2020 16 Strategy 142 Statement of Changes in Fixed Assets 25 Internal Management System 143 Notes for the fiscal year 2020 31 Sustainability 147 Notes to the Balance Sheet 40 Research and Development 157 Notes to the Income Statement 57 People 161 Other Disclosures 165 Members of the Executive Board 67 Report on Economic Position of Merck KGaA, Darmstadt, Germany 67 Macroeconomic and 166 Members of the Supervisory Board Sector-Specific Environment of Merck KGaA, Darmstadt, Germany 71 Review of Forecast 168 Disclosures in accordance with against Actual Business Developments section 160 (1) no. 8 of the German 79 Course of Business and Economic Position Stock Corporation Act (AktG) 79 Group 170 List of Shareholdings of Merck KGaA, Darmstadt, Germany, as of December 31, 2020 89 Healthcare 194 Reproduction of the Independent Auditor’s 95 Life Science Report 99 Performance Materials 201 Responsibility Statement in accordance 103 Corporate and Other with section 264 (2) sentence 3 HGB and section 289 (1) sentence 5 HGB 104 Report on Risks and Opportunities 202 Report of the Supervisory Board 121 Report on Expected Developments 206 Financial Calendar 126 Report in accordance with Section 315a (1) of the German Commercial Code (HGB) 129 Additional Information
    [Show full text]
  • Annual Report 2017
    350 Annual Report 2017 1668 Excerpt from the “Pharmacy Privilege” issued by the ruling court to the company founder FRIEDRICH JACOB MERCK: “ [He shall run the pharmacy] ensuring that it is properly stocked with good, freshly prepared medicinal products at all times so as to cure ailments and prevent ill health.” 2018 STEFAN OSCHMANN Chairman of the Executive Board and CEO of Merck “ Scientific curiosity has been a major driver of our success for 350 years. It has enabled us to pioneer new technologies. And now we are helping to shape the digital revolution.” THOUGHTS ON THE FUTURE SIMON CLARK Six young researchers is a PhD student in climate physics at the University of Exeter. His YouTube videos also mainly address topics in physics. “ Things only improve if there are people who have crazy ideas and try out something new.” Does Merck drive fresh ideas? Find the answer on page 10. SAMUEL CUNHA is a Brazilian parasitologist who shares his passion for biology with numerous followers on YouTube. “ To stay passionate, we always have to think of the future,of the poten- tial result of our work.” What does Merck think of this principle? Find the answer on page 11. EVA AMSEN is a biochemist, writer and science communicator based in London. “ For scientists it is important to exchange ideas not only with their colleagues, but also with people from totally different fields – for example, with artists.” Does Merck practice interdisciplinary exchange? Find the answer on page 13. INÉS DAWSON is a biologist, a PhD student at Oxford and a popular YouTube blogger.
    [Show full text]
  • Externer/Interner Brief, Telefax Für Word 2000, Merck Darmstadt
    Progress Report Implementation of the ten principles of the UN Global Compact Period: May 2011 to December 2012 CEO’s Declaration of continued support We at Merck take our corporate responsibility seriously − it is an integral part of our entrepreneurial approach. Responsible conduct founded on clearly defined values is a key factor in Merck nearing its 350th anniversary. We would like to continue along this path. We are therefore reaffirming our commitment to the United Nations Global Compact, which we joined in 2005. We continue to support the ten principles established by the compact, which cover human rights, labor regulations, environmental protection, and anti-corruption. One example of how we actively promote human rights is our commitment to access to health, which means facilitating access to medicines for people in developing countries. After all, according to Article 25 of the UN’s Universal Declaration of Human Rights, medical care is a universal human right. Being a pharmaceutical, chemical and life science company, we can contribute our expertise in a particularly meaningful manner here. For example, we are collaborating with the World Health Organization (WHO) to combat the tropical disease schistosomiasis in Africa, where we aim to help eliminate the disease by donating praziquantel tablets. In 2012, we decided to expand our commitment and increase the tablet donation tenfold, from 25 million per year to 250 million per year in the medium term. Our Praziquantel Donation Program is, however, only one of many examples of how we are implementing the principals of the Global Compact at Merck despite economically challenging times.
    [Show full text]
  • Merck Serono Constantly Seeks: • Novel Therapeutic Agents and Drug Targets in Our Key Therapeutic Areas
    PharmaForum 2010, am 2. November in Mainz 1. Company Merck is the world’s oldest pharmaceutical and chemical company with approximately 40.000 employers in 64 countries. Its roots date back to 1668, when Friedrich Jacob Merck purchased the "Angel Pharmacy" in Darmstadt – still owned by the Merck family today. Around 30% of the company’s total capital is publicly traded, while the Merck family owns an interest of about 70% via the general partner E. Merck KG. Merck shares have been included in the DAX ® 30 since 2007. In early 2007, the acquisition of the Swiss firm Serono, Europe’s leading biopharmaceutical company, was completed. The scope of this strategically compelling combination is expected to raise Merck’s competitiveness in the global pharmaceutical market. Analogical, Merck strengthened its chemical sector with the acquisition of Millipore in 2010. 2. Core Competences 2.1 Pharmaceuticals Merck discovers, develops, manufactures and markets innovative prescription drugs as well as over-the-counter products. Merck develop therapies for high unmet medical needs. Through their targeted effect, these help patients to live a longer and better life. Our over-the-counter products can prevent disease and relieve minor complaints. Key therapeutic areas and products ⇒ Oncology: Erbitux® (metastatic colorectal cancer, head and neck cancer), UFT® (colorectal cancer) ⇒ Neurodegenerative Diseases: Rebif® (multiple sclerosis) ⇒ Fertility: Gonal-f®, Ovitrelle®, Pergoveris™, Luveris®, Crinone®, Cetrotide® ⇒ Endocrinology: Saizen® (growth hormone disorders), Serostim® (HIV- associated wasting), Kuvan® (phenylketonuria) ⇒ CardioMetabolic Care: Glucophage® family (type 2 diabetes), Concor® family (cardiovascular diseases), Euthyrox® (thyroid diseases) ⇒ Other therapeutic areas: Cyanokit® (cyanide poisoning) and other products Seite 2 2.2 Chemicals With a range of more than 40.000 products, Merck Millipore ranks third in the life science market.
    [Show full text]
  • Annual Report 2014 Delivering Growth
    ANNUAL REPORT 2014 DELIVERING GROWTH MERCK GROUP → KEY FIGURES Change € million 2014 2013 in % Total revenues 11,500.8 11,095.1 3.7 Sales 11,291.5 10,700.1 5.5 Operating result (EBIT) 1,762.0 1,610.8 9.4 Margin (% of sales) 15.6 15.1 EBITDA 3,122.9 3,069.2 1.7 Margin (% of sales) 27.7 28.7 EBITDA pre one-time items 3,387.7 3,253.3 4.1 Margin (% of sales) 30.0 30.4 Earnings per share (€)1 2.66 2.77 –4.0 Earnings per share pre one-time items (€)1 4.60 4.39 4.8 Business free cash flow 2,605.1 2,960.0 –12.0 1 Taking into account the share split; previous year’s figures have been adjusted accordingly. See “Earnings per share” in the Notes to the Consolidated Financial Statements. MERCK GROUP → SALES € million 2014 → 11,291.5 2013 → 10,700.1 2012 → 10,740.8 2011 → 9,905.9 2010 → 8,928.9 MERCK GROUP → EBITDA PRE ONE-TIME ITEMS € million 2014 → 3,387.7 2013 → 3,253.3 2012 → 2,964.9 2011 → 2,723.8 2010 → 2,545.0 MERCK GROUP → Merck is a leading company for innovative and top-quality high- tech products in healthcare, life science and performance materials. Around 39,000 Merck employees work in 66 countries MERCK GROUP MERCK structure Company to improve the quality of life for patients, to foster the success → of customers and to help meet global challenges. MERCK GROUP → BUSINESS SECTORS AND BUSINESSES as of January 1, 2015 Merck Group Performance Healthcare Life Science Business sectors Materials Performance Merck Serono Merck Millipore Materials Businesses Consumer Health Allergopharma Biosimilars Effective January 1, 2015 Merck changed the structure of its financial reporting.
    [Show full text]
  • Aldrichimica Acta 34, 2001
    1951–2001: FIFTY YEARS OF CHEMISTS HELPING CHEMISTS AldrichimicaAldrichimica AACTACTA VOL.34, NO.1 • 2001 Preparation of Optically Active α-Amino Acids Alkoxymethylenemalonates in Organic Synthesis CHEMISTS HELPING CHEMISTS 53,182-0 N,N’-Di-(tert-butoxycarbonyl)thiourea, 97% 54,548-1 (1R,2S)-1-Phenyl-2-(1-pyrrolidinyl)-1-propanol, 98% 54,897-9 (1S,2R)-1-Phenyl-2-(1-pyrrolidinyl)-1-propanol, 98% O S O This diprotected thiourea is widely used in the synthesis of heterocycles, including a ONN O H H pentacyclic guanidine system as an These norephedrine derivatives are intermediate to ptilomycalin A,1 and, recently, HO N HO N useful chiral mediators and have in the preparation of p-N,N’-bis-Boc-guanidophenol, a key intermediate for the applications in the enantioselective preparation of a series of aryl o-aroylbenzoates as serine protease inhibitors.2 CH3 CH3 addition of acetylides to carbonyl (1) Nagasawa, K. et al. Tetrahedron 2000, 56, 187. (2) Jones, P.B.; Porter, N.A. J. Am. Chem. Soc. compounds. Examples include the 54,548-1 54,897-9 1999, 121, 2753. synthesis of the HIV-1 reverse transcriptase inhibitor DMP 2661 and the enantioselective addition of diethylzinc to aldehydes.2 54,036-6 1,1-Diethoxy-3-methyl-2-butene, 97% (1) Pierce, M.E. et al. J. Org. Chem. 1998, 63, 8536. (2) Soai, K. et al. ibid. 1991, 56, 4264. OEt This acetal has been utilized in the synthesis of the related 1-alkoxy-3-phenylselenoalkenes and 3-phenylselenoalkanals,1 OEt and in the preparation of 2,2-dimethylchromenes from 54,174-5 Tri-O-acetyl-β-D-arabinosylbromide, 95% electron-deficient phenols.2 (1) Nishiyama, Y.
    [Show full text]
  • Annual Report (PDF)
    Annual Report 2015 STRONGER DISCLAIMER Publication of Merck KGaA, Darmstadt, Germany. In the United States and Canada the subsidiaries of Merck KGaA, Darmstadt, Germany, operate as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Performance Materials. To reflect such fact and to avoid any misconception of the reader of the publication certain logos, terms and names of businesses of the publication have been substituted or additional descriptions have been added. This version of the publication, therefore, slightly deviates from the otherwise identical version of the publication provided outside the United States and Canada. GROUP Key figures Change € million 2015 2014 in % Net sales1 12,844.7 11,362.8 13.0 Operating result (EBIT) 1,843.2 1,762.0 4.6 Margin (% of net sales)1 14.3 15.5 EBITDA 3,354.1 3,122.9 7.4 Margin (% of net sales)1 26.1 27.5 EBITDA pre exceptionals 3,629.8 3,387.7 7.1 Margin (% of net sales)1 28.3 29.8 Earnings per share (€) 2.56 2.66 – 3.8 Earnings per share pre exceptionals (€) 4.87 4.60 5.9 Business free cash flow 2,766.2 2,605.1 6.2 1 The composition of net sales has changed, see ‟Changes to accounting and measurement principles and disclosure changes” in the Notes to the Group accounts. GROUP Net sales € million and 2015 12,844.7 Structure 2014 11,362.8 Group 2013 10,735.3 2012 10,755.7 2011 9,922.2 GROUP EBITDA pre exceptionals € million 2015 3,629.8 2014 3,387.7 2013 3,253.3 2012 2,964.9 2011 2,723.8 GROUP Business sectors and businesses Group Performance Business Healthcare Life Science Materials sectors Performance Biopharma Life Science Businesses Materials Consumer Health Allergopharma Biosimilars Our company has fundamentally changed over the past ten years.
    [Show full text]
  • Merck Annual Report 2011 Merck Serono
    Merck Annual Report 2011 Merck Serono Performance Materials Consumer Health Care Merck Millipore WorldReginfo - b22947e7-2f02-43db-afbc-1c13bb2a5cb7 Contents The road to tomorrow #01 To our Shareholders 023 ➝ Letter from Karl-Ludwig Kley 026 ➝ The Executive Board 028 ➝ Merck in the Capital Market 032 ➝ Key Events in 2011 #02 Group Management Report 035 ➝ Overall Economic Situation 036 ➝ Financial Position and Results of Operations 050 ➝ Corporate Responsibility 060 ➝ Merck Serono 071 ➝ Consumer Health Care 075 ➝ Merck Millipore 079 ➝ Performance Materials 083 ➝ Corporate and Other 084 ➝ Risk Report 091 ➝ Report on Expected Developments 098 ➝ Subsequent Events #03 Corporate Governance 101 ➝ Statement on Corporate Governance 119 ➝ Report of the Supervisory Board 122 ➝ Objectives of the Supervisory Board with respect to its composition #04 Consolidated Financial Statements for 2011 126 ➝ Consolidated Income Statement 127 ➝ Consolidated Statement of Comprehensive Income 128 ➝ Consolidated Balance Sheet 129 ➝ Consolidated Cash Flow Statement 130 ➝ Consolidated Statement of Changes in Net Equity 132 ➝ Notes to the Group accounts #05 More Information 204 ➝ Responsibility Statement 205 ➝ Auditor’s Report 206 ➝ Glossary 212 ➝ Financial Calendar for 2012 Inside the back cover ➝ Business Development 2002 – 2011 ➝ Awards, Service, Publication Contributors WorldReginfo - b22947e7-2f02-43db-afbc-1c13bb2a5cb7 Contents The Merck Group In brief Key figures of the Merck Group Pharma­ Corporate Change € million ceuticals Chemicals and Other Total in % Total
    [Show full text]
  • Single Entity Report Merck Kgaa, Darmstadt, Germany
    Science …is at the heart of everything we do. MERCK KGAA, DARMSTADT, GERMANY ANNUAL FINANCIAL STATEMENTS 2018 DISCLAIMER Publication of Merck KGaA, Darmstadt, Germany. In the United States and Canada the subsidiaries of Merck KGaA, Darmstadt, Germany, operate as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Performance Materials. To reflect such fact and to avoid any misconception of the reader of the publication certain logos, terms and names of businesses of the publication have been substituted or additional descriptions have been added. This version of the publication, therefore, slightly deviates from the otherwise identical version of the publication provided outside the United States and Canada. € 2.2 BILLION invested in research and development in 2018. Around 52,000 hearts beat for science. Employees in 66 countries share a passion for pushing boundaries and making new discoveries. Since 1668, our name has stood for the positive power of science. Table of Contents Combined Management Report 004 – 112 005 Fundamental Information about the Group 005 The Group Annual Financial 011 Strategy Statements 018 Internal Management System 114 – 166 022 Corporate Responsibility 114 Balance Sheet as of 031 Research and Development December 31, 2018 041 People 115 Income Statement for the period from January 1 to December 31, 2018 051 Report on Economic Position 116 Statement of Changes in Fixed Assets 051 Macroeconomic and Sector-Specific Environment 117 Notes to the Annual Financial 054 Review of Forecast against Statements Actual Business Developments 119 Notes to the Balance Sheet 061 Course of Business and 127 Notes to the Income Statement Economic Position 131 Other Disclosures - Group 134 Members of the Executive Board of - Healthcare Merck KGaA, Darmstadt, Germany - Life Science 135 Supervisory Board - Performance Materials 136 Disclosures in accordance with - Corporate and Other section 160 (1) no.
    [Show full text]